Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will host an investor webcast to discuss new data from the bioMUSE Natural History Study and its implications for the ATH434-202 Phase 2 trial endpoints. The webcast, set for May 29, 2024, in the U.S. and May 30, 2024, in Australia, will feature CEO Dr. David Stamler and Professor Daniel Claassen from Vanderbilt University. Dr. Claassen, a key opinion leader and principal investigator, will provide insights into the study results and their impact. Registration is required to attend the webcast, where investors can ask questions.

Positive

• New bioMUSE data informs ATH434-202 study endpoints, potentially enhancing clinical trial outcomes.
• Webcast includes participation of key opinion leader Dr. Daniel Claassen, adding credibility.
• Opportunity for investors to engage and ask questions reflects transparency and investor relations.

Negative

• No immediate financial data or specific milestones achieved were provided in the PR.
• Investor reliance on future results may increase uncertainty around stock performance.
• Registration required may limit access and reduce potential investor engagement.

- New bioMUSE Data Informs ATH434-202 Study Endpoints -

- Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University -

MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 2024 in the United States. Details are listed below and registration is required.

The call will feature Alterity’s CEO Dr. David Stamler who will discuss the bioMUSE Natural History Study results and their impact on the endpoints for the ATH434-202 Phase 2 clinical trial. Joining the call will be key opinion leader Daniel Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical Center. Dr. Claassen is the Principal Investigator of bioMUSE and the Coordinating Investigator of the ATH434-201 Phase 2 clinical trial.

Webcast details

AUSTRALIA PARTICIPANTS:
	Date:	Thursday, 30 May 2024
	Time:	10:00 a.m. AEST (Sydney/Melbourne)
UNITED STATES PARTICIPANTS:
	Date:	Wednesday, 29 May 2024
	Time:	5:00 p.m. Pacific Time
		8:00 p.m. Eastern Time

Register for the Zoom webcast: https://bit.ly/3yFXHMp
Registration is required and dial in details will be sent directly upon registration.

Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation. Investors are also able to submit questions in advance to Hannah Howlett at we-aualteritytherapeutics@we-worldwide.com

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064

U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386

FAQ

What is the significance of the new bioMUSE data for ATHE?

The new bioMUSE data provides critical information for assessing endpoints in the ATH434-202 Phase 2 clinical trial.

When is Alterity Therapeutics hosting the webcast?

Alterity Therapeutics is hosting the webcast on May 29, 2024, in the U.S. and May 30, 2024, in Australia.

Who will be featured in the Alterity Therapeutics webcast?

The webcast will feature CEO Dr. David Stamler and key opinion leader Dr. Daniel Claassen from Vanderbilt University.

How can investors participate in the Alterity Therapeutics webcast?

Investors can participate by registering via the provided link. They will receive dial-in details upon registration and can ask questions during the call.

What will be discussed during the Alterity Therapeutics webcast?

The webcast will discuss the results of the bioMUSE Natural History Study and its impact on the ATH434-202 Phase 2 clinical trial endpoints.